Handok to launch Tritace Protect.

Published: 2006-03-21 06:59:00

Updated: 2006-03-21 06:59:00

Handok launched a cardiovascular protective drug called "Tritace Protect" (ramipril 10mg) in to the Korean market, which was earlier proven of its therapeutic benefits through the studies of "HOPE: heart outcomes prevention evaluation" and "HOPE TOO: the ongoing outcomes". So far Tritace 2.5mg an...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK